Study Uncovers Crucial Role of Prostacyclin in Fetal Membrane Healing

When a pregnant woman's water breaks too early, it often leads to preterm birth, with no effective method to prevent or treat it. Researchers have discovered that the lipid molecule prostacyclin plays a key role in the repair of fetal membrane rupture. The findings from a novel study in The American Journal of Pathology, published by Elsevier, provide new insights into the mechanisms of fetal membrane healing and may open avenues for the development of therapeutic strategies to enhance membrane repair and prevent preterm birth.

“Preterm birth is a major challenge in obstetrics, and it poses both medical and social problems. Infants born preterm have a significantly higher risk of perinatal mortality and morbidity,” explains lead investigator Haruta Mogami, MD, PhD, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine.

Preterm prelabor rupture of membranes (pPROM) is one of the leading causes of preterm birth, occurring in approximately 1% of all pregnancies, and 25% to 30% of preterm births follow pPROM. Although spontaneous healing of fetal membranes is rare and occasionally observed in clinical settings, the underlying mechanisms remain poorly understood. The current research investigated the mechanisms of repair and regeneration of ruptured fetal membranes to address this gap in clinical care, focusing on the role of prostaglandins—a family of hormone-like substances—and prostacyclin, a specific member of this family known to relax blood vessels and prevent clotting.

Using a mouse model of fetal membrane rupture, investigators examined the molecular and cellular responses at the rupture site, with a focus on prostaglandin signaling.

The most significant finding is that prostacyclin signaling through the prostacyclin receptor (IP) plays a crucial role in the repair of fetal membranes by promoting healing through the proliferation and migration of amnion mesenchymal cells.

Other key findings include:

• In ruptured membranes, genes responsible for activating prostaglandin signaling and prostacyclin itself were significantly elevated at the site of the tear.

• The number of amnion mesenchymal (repair) cells at the rupture site increased as well as the enzymes creating prostacyclin.

• Pharmacological inhibition of the prostacyclin receptor (IP) impaired the repair of the amnion and led to reduced proliferation of amnion mesenchymal cells.

• When the repair signal was activated again via treatment with an IP receptor agonist, it led to partially rescued membrane repair.

• IP-deficient mouse fetuses exhibited compromised membrane healing and significantly fewer proliferating mesenchymal cells at the rupture site compared to wild-type controls.

• Complementary in vitro experiments with cultured human amnion mesenchymal cells demonstrated that IP activation enhanced both proliferation and migration of these cells, while IP antagonism had inhibitory effects, confirming the same repair mechanism exists in humans.

“We used to think that prostaglandins were only involved in inducing uterine contraction and cervical ripening during pregnancy. In this study, we clarified that prostacyclin not only relaxes the myometrium and maintains pregnancy but—when locally synthesized at the ruptured amnion—it also helps the wound heal,” notes lead author Masahito Takakura, MD, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine.

Dr. Mogami concludes, “We were surprised to find that among various prostaglandins, only prostacyclin was specifically upregulated at the rupture site, highlighting a more selective and targeted role than we had expected. This discovery provides new insight into the mechanisms of fetal membrane healing, which could eventually lead to new therapeutic strategies for managing pPROM and reducing the risk of preterm birth and infant mortality.”

Notes for editors

The article is “Prostacyclin Assists in the Repair of Ruptured Amnions through the Proliferation and Migration of Amnion Mesenchymal Cells,” by Masahito Takakura, Yosuke Kawamura, Yusuke Ueda, Sunao Matsuzaka, Eriko Yasuda, Yu Matsuzaka, Asako Inohaya, Yoshitsugu Chigusa, Masaki Mandai, Shuh Narumiya, Koh-ichi Yuhki, and Haruta Mogami (https://doi.org/10.1016/j.ajpath.2025.06.002). It appears in The American Journal of Pathology, volume 195, issue 10 (October 2025), published by Elsevier.

The article is openly available at https://ajp.amjpathol.org/article/S0002-9440(25)00234-2/fulltext.

Full text of the article is also available to credentialed journalists upon request. Contact Eileen Leahy at +1 732 406 1313 or [email protected] to request a PDF of the article or more information. To reach the study’s authors, contact Haruta Mogami, MD, PhD, at [email protected].

About The American Journal of Pathology

The American Journal of Pathology, official journal of the American Society for Investigative Pathology, published by Elsevier, seeks high-quality original research reports, reviews, and commentaries related to the molecular and cellular basis of disease. The editors will consider basic, translational, and clinical investigations that directly address mechanisms of pathogenesis or provide a foundation for future mechanistic inquiries. Examples of such foundational investigations include data mining, identification of biomarkers, molecular pathology, and discovery research. High priority is given to studies of human disease and relevant experimental models using molecular, cellular, and organismal approaches. ajp.amjpathol.org

關於 Elsevier

身為科學資訊與分析的全球領導者，Elsevier 協助研究人員與醫療照護專業人員推動科學發展，改善醫療成果，造福社會。我們以可信賴、以實證為基礎的內容和先進的 AI 數位技術為基礎，透過創新的解決方案促進洞察力和關鍵決策。

140 多年來，我們一直為研究和醫療保健界的工作提供支援。我們全球 9,500 名員工，包括 2,300 名技術人員，致力於支援研究人員、圖書館館長、學術領袖、資金提供者、政府、研發密集型公司、醫生、護士、未來醫療保健專業人員和教育工作者的重要工作。我們的 2,900 種科學期刊和經典參考工具書包括其領域中最重要的書籍，包括 Cell Press、The Lancet 和 Gray's Anatomy。 我們與愛思唯爾基金會 (Elsevier Foundation) 合作，與我們服務的社群攜手合作，在發展中國家和世界各地的科學、研究和醫療保健領域推動包容性和多樣性。 Elsevier 是 RELX 的一部分，RELX 是一家為專業和商業客戶提供以資訊為基礎的分析和決策工具的全球供應商。有關我們的工作、數位解決方案和內容的更多資訊，請造訪 www.elsevier.com 。